Literature DB >> 32454629

A Cost Saving and Waste Minimization Study About Handling of the Antineoplastic Agents.

Metin Deniz Karakoç1.   

Abstract

OBJECTIVES: As a cancer treatment option, chemotherapy costs make up a large part of the budgets of social insurance foundations and related expenditures are increasing continuously annually. Cost saving and waste minimizing strategies are required to reduce the expenditures in the field of oncology. The study aimed to reduce the amount of wasted antineoplastic drugs and medical supply consumption.
MATERIALS AND METHODS: The study explains why vials with a larger size and drugs in liquid form should be preferred over various smaller sizes and powder forms of antineoplastic preparations.
RESULTS: Amounts of drug wastage, vial adaptor, and transfer set consumption data were recorded regularly for a period of seven months. The average vial adaptor consumption per patient in the last three months decreased from 5 to 3.3. The preference of liquid forms as much as possible instead of powder forms, which has a shorter stability time after dilution, and the choice of larger package sizes of frequently used drugs decreased vial adaptor consumption. Potential savings were calculated as around 31.660 USD annually. Costs of total wasted doses were 8.699.87 USD, and the whole antineoplastic drug consumption was 515.500 USD during the study. A decrease of 0.58 USD was observed per capita when the first and last three-month periods were compared in terms of waste costs.
CONCLUSION: These values indicate that the reduction of wasted drugs have potential annual savings of 3.375 USD. It is shown that total potential savings of 35.000 USD could be made per year. By implementing the same principles in all hospitals in Turkey, approximately 2.8 million USD could be made annually. The pharmaceutical industry and hospital pharmacists have important responsibilities in this issue. ©Copyright 2017 Turk J Pharm Sci, Published by Galenos Publishing House.

Entities:  

Keywords:  Antineoplastic; chemotherapy; cost saving; drug waste; pharmacoeconomy

Year:  2017        PMID: 32454629      PMCID: PMC7227926          DOI: 10.4274/tjps.25238

Source DB:  PubMed          Journal:  Turk J Pharm Sci        ISSN: 1304-530X


  28 in total

1.  Ideal vial size for bortezomib: real-world data on waste and cost reduction in treatment of multiple myeloma in Brazil.

Authors:  Luciana Clark; Ana Paula Castro; Anna Flávia Fortes; Fábio Santos; Otávio Clark; Tobias Engel; Bruna Pegoretti; Vanessa Teich; Denizar Vianna; Fabíola Puty
Journal:  Value Health       Date:  2011 Jul-Aug       Impact factor: 5.725

2.  Cost savings from dose rounding of biologic anticancer agents in adults.

Authors:  Brenda J Winger; Elizabeth A Clements; Jaculin L DeYoung; Timothy J O'Rourke; Deborah L Claypool; Steve Vachon; Thomas H VanDyke; Jennifer Zimmer-Young; Polly E Kintzel
Journal:  J Oncol Pharm Pract       Date:  2010-03-23       Impact factor: 1.809

3.  SFPO and ESOP recommendations for the practical stability of anticancer drugs: an update.

Authors:  J Vigneron; A Astier; R Trittler; J D Hecq; M Daouphars; I Larsson; B Pourroy; F Pinguet
Journal:  Ann Pharm Fr       Date:  2013-08-28

Review 4.  Dose calculation of anticancer drugs.

Authors:  Bo Gao; Heinz-Josef Klumpen; Howard Gurney
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-10       Impact factor: 4.481

5.  Evaluation of a closed-system cytotoxic transfer device in a pharmaceutical isolator.

Authors:  N Vyas; A Turner; J M Clark; G J Sewell
Journal:  J Oncol Pharm Pract       Date:  2014-07-29       Impact factor: 1.809

6.  Rising cost of anticancer drugs in Australia.

Authors:  D J Karikios; D Schofield; G Salkeld; K P Mann; J Trotman; M R Stockler
Journal:  Intern Med J       Date:  2014-05       Impact factor: 2.048

Review 7.  Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics.

Authors:  Angelo Paci; Gareth Veal; Christophe Bardin; Dominique Levêque; Nicolas Widmer; Jos Beijnen; Alain Astier; Etienne Chatelut
Journal:  Eur J Cancer       Date:  2014-06-02       Impact factor: 9.162

8.  A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe.

Authors:  George Dranitsaris; Ana Ortega; Martie S Lubbe; Ilse Truter
Journal:  J Oncol Pharm Pract       Date:  2011-03-07       Impact factor: 1.809

9.  Microbial inhibitory properties and stability of topotecan hydrochloride injection.

Authors:  K Patel; S B Craig; M G McBride; N R Palepu
Journal:  Am J Health Syst Pharm       Date:  1998-08-01       Impact factor: 2.637

10.  It is not only the empty vials that go into the garbage can during chemotherapy drugs preparation: a cost analysis of unused chemotherapy drugs in cancer treatment.

Authors:  A Ata; H Abali; E Yengel; A Arican
Journal:  J BUON       Date:  2012 Oct-Dec       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.